Breaking New Ground -- Forest Laboratories, Inc. Expands to Canadian Market

Breaking New Ground -- Forest Laboratories, Inc. Expands to Canadian Market 
Forest Laboratories Canada Inc. focused on bringing new treatment options to 
patients 
TORONTO, Jan. 22, 2013 /CNW/ - Forest Laboratories, Inc. (NYSE: FRX) - an 
international pharmaceutical company - today announced its entry into the 
Canadian market through its wholly owned subsidiary Forest Laboratories Canada 
Inc. This development is in furtherance of Forest's plans to expand in global 
markets. 
"We are excited about our venture in the Canadian marketplace," said Greg 
Engel, General Manager, Forest Laboratories Canada Inc. "We intend to 
introduce products that offer new treatment options that can address unmet 
medical needs and help improve patients' medical conditions. The company's 
goal is to bring important therapies to those Canadians who need them in 
compliance with Rx&D's Code of Ethical Practices. In the near-term, Forest 
Laboratories Canada Inc. is focused on bringing a number of therapeutic 
options to market in the areas of cardiology, respiratory medicine, 
gastroenterology, and mental health." 
The Canadian head office is based in Toronto, Ontario, with a sales team that 
will reach from coast-to-coast. 
About Forest Laboratories Canada Inc. & Forest Laboratories, Inc. 
Forest Laboratories Canada Inc., the Canadian operation of Forest 
Laboratories, Inc. (NYSE: FRX), is dedicated to delivering innovative 
healthcare solutions across multiple therapeutic areas to patients with unmet 
medical needs. Forest Laboratories Canada Inc. is headquartered in Toronto, 
Ontario. To learn more, visit www.frx.ca. 
Forest Laboratories, Inc.'s longstanding global partnerships and track record 
developing and marketing pharmaceutical products in the United States have 
yielded its well-established central nervous system and cardiovascular 
franchises and innovations in anti-infective, respiratory, gastrointestinal 
and pain management medicine. Forest Laboratories, Inc.'s pipeline, the most 
robust in its history, includes product candidates in all stages of 
development across a wide range of therapeutic areas. Forest Laboratories, 
Inc. is headquartered in New York, NY. To learn more, visit www.FRX.com. 
Except for the historical information contained herein, this release may 
contain forward-looking statements within the meaning of United States 
securities laws. These statements may involve a number of risks and 
uncertainties, including the difficulty of predicting regulatory approvals, 
the acceptance and demand for new pharmaceutical products, the impact of 
competitive products and pricing, the timely development and launch of new 
products, and the risk factors listed from time to time in Forest 
Laboratories, Inc.'s Annual Report on Form 10-K, Quarterly Reports on Form 
10-Q, and any subsequent U.S. Securities and Exchange Commission filings. 
Neither Forest Laboratories Canada Inc. nor Forest Laboratories, Inc. assumes 
any obligation to update any forward-looking statements contained in this 
release to reflect new information or future events or developments. 
Frank J. Murdolo VP Investor Relations Forest Laboratories, Inc. 212-224-6714 
media.relations@frx.com 
Jacqueline Zonneville NATIONAL Public Relations 416-848-1398 
jzonneville@national.ca 
SOURCE: Forest Laboratories Canada Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/January2013/22/c7410.html 
CO: Forest Laboratories Canada Inc.
ST: Ontario 
-0- Jan/22/2013 14:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.